💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Naftazone

CHEMBL2106794 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
215.2 g/mol
LogP
2.0
Phase
4

A hemostatic agent used in some countries to reduce capillary fragility and control minor bleeding, particularly in conditions such as hemorrhoids and venous insufficiency. It is thought to strengthen blood vessel walls and improve their resistance to leakage.

Molekularmasse

215,2100 g/mol

LogP

2,00

TPSA

88,00 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Promotes blood clotting and hemostasis through enhancement of the coagulation cascade, platelet aggregation, or direct provision of clotting factors.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Promotes blood clotting and hemostasis through enhancement of the coagulation cascade, platelet aggregation, or direct provision of clotting factors.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
NC(=O)N/N=C1\C=Cc2ccccc2C1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C11H9N3O2/c12-11(16)14-13-9-6-5-7-3-1-2-4-8(7)10(9)15/h1-6H,(H3,12,14,16)/b13-9+

                

                

                

                    
                    

                        
Molecular Formula

                        
C11H9N3O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
Rotierbare Bindungen

                        
1

                    

                    
                    
                    

                        
Schwere Atome

                        
16

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
A hemostatic agent used in some countries to reduce capillary fragility and control minor bleeding, particularly in conditions such as hemorrhoids and venous insufficiency. It is thought to strengthen blood vessel walls and improve their resistance to leakage.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Promotes blood clotting and hemostasis through enhancement of the coagulation cascade, platelet aggregation, or direct provision of clotting factors.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Naftazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2106794.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 71688.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.